Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma

NCT02558894 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

65

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: MEDI4736 monotherapy
DRUG: tremelimumab+MEDI4736

Sponsor

AstraZeneca